(Z)-benzyl amino(methylthio)methylenecarbamate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (Z)-benzyl amino(methylthio)methylenecarbamate
• 英文别名: N-[Imino(methylthio)methyl]-carbamicAcidPhenylmethylEster；benzyl N-(C-methylsulfanylcarbonimidoyl)carbamate
• 化学式: C₁₀H₁₂N₂O₂S
• 分子量: 224.283
• InChiKey: ZHNUXJSPYNQQHV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  90
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (Z)-benzyl amino(methylthio)methylenecarbamate 在 三乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.33h， 生成 tert-butyl (10S)-10-(((benzyloxy)carbonyl)amino)-14-((Z)-3-(((benzyloxy)carbonyl)imino)-5,7-dioxo-9-phenyl-8-oxa-2,4,6-triazanonyl)-5-imino-13-methyl-3,12-dioxo-1-phenyl-2-oxa-4,6,13-triazapentadecan-15-oate
  参考文献：
  名称：

  Total Synthesis of the Anti Methicillin-Resistant Staphylococcus aureus Peptide Antibiotics TAN-1057A-D

  摘要：

  TAN-1057A-D, dipeptides isolated from bacteria Flexibacter sp. PK-74 and PK-176, are new antibiotics with potent antibacterial activity against methicillin-resistant Staphylococcus aureus. We describe, in detail, the total synthesis of TAN-l057A-D by a convergent route featuring a new method to construct the cyclic amidinourea functional group.

  DOI：

  10.1021/ja972670j
• 作为产物：
  描述：

  氯甲酸苄酯 、 2-甲基-2-疏基硫酸脲 在 sodium hydroxide 作用下， 以 正己烷 、 水 为溶剂， 以70%的产率得到(Z)-benzyl amino(methylthio)methylenecarbamate
  参考文献：
  名称：

  Novel anticoagulant agmatine derivatives and process for the preparation

  摘要：

  公开了具有公式X-Pro-Agm(HB) (.sub.n)的抗凝剂，其中X是具有苯基、苯基-（较低）烷基或苯基-（含杂原子）较低烷基侧链构型的α-氨基酸基团，Agm是一种精氨酸基团（1-氨基-4-胍基-丁烷），B是一个酸残基，n是0-2之间的整数。

  公开号：

  US04346078A1

文献信息

• Substituted 5-membered ring heterocycles, their preparation and their use
  申请人：Hoechst Aktiengesellschaft

  公开号：US05981492A1

  公开（公告）日：1999-11-09

  The present invention pertains to 5-ring heterocycles of general formula (I), wherein W, Y, Z, B, D, E and R as well as b, c, d, e, f, g, and h are as indicated in the description; to methods for preparing them, and to their use as inhibitors of platelet aggregation, metastasizing of carcinomatous cells and the attachment of osteoclasts to the bone surface. ##STR1##

  本发明涉及一般式（I）的5-环杂环化合物，其中W、Y、Z、B、D、E和R以及b、c、d、e、f、g和h如描述中所示；以及其制备方法，以及它们作为抑制血小板聚集、癌细胞转移和破骨细胞附着于骨表面的用途。
• BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Blaquiere Nicole

  公开号：US20110076291A1

  公开（公告）日：2011-03-31

  Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N; Z 2 is CR 2 or N; Z 3 is CR 3 or N; Z 4 is CR 4 or N; and where (i) X 1 is N and X 2 is S, (ii) X 1 is S and X 2 is N, (iii) X 1 is CR 7 and X 2 is S, (iv) X 1 is S and X 2 is CR 7 ; (v) X 1 is NR 8 and X 2 is N, (vi) X 1 is N and X 2 is NR 8 , (vii) X 1 is CR 7 and X 2 is O, (viii) X 1 is O and X 2 is CR 7 , (ix) X 1 is CR 7 and X 2 is C(R 7 ) 2 , (x) X 1 is C(R 7 ) 2 and X 2 is CR 7 ; (xi) X 1 is N and X 2 is O, or (xii) X 1 is O and X 2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  Formula I中的苯并氧杂环化合物，包括立体异构体、几何异构体、互变异构体、溶剂化合物、代谢物和其药学上可接受的盐，其中：Z1为CR1或N；Z2为CR2或N；Z3为CR3或N；Z4为CR4或N；其中（i）X1为N且X2为S，（ii）X1为S且X2为N，（iii）X1为CR7且X2为S，（iv）X1为S且X2为CR7；（v）X1为NR8且X2为N，（vi）X1为N且X2为NR8，（vii）X1为CR7且X2为O，（viii）X1为O且X2为CR7，（ix）X1为CR7且X2为C(R7)2，（x）X1为C(R7)2且X2为CR7；（xi）X1为N且X2为O，或（xii）X1为O且X2为N，用于抑制脂质激酶，包括p110α和PI3K的其他同工酶，并用于治疗由脂质激酶介导的癌症等疾病。公开了利用Formula I中的化合物在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病或相关病理状况的方法。
• Discovery of an Orally Active Non-Peptide Fibrinogen Receptor Antagonist Based on the Hydantoin Scaffold
  作者：Hans Ulrich Stilz、Wolfgang Guba、Bernd Jablonka、Melitta Just、Otmar Klingler、Wolfgang König、Volkmar Wehner、Gerhard Zoller

  DOI：10.1021/jm001068s

  日期：2001.4.1

  Antagonists of the platelet fibrinogen receptor (GP IIb/IIIa receptor) are expected to be a promising new class of antithrombotic agents. The binding of fibrinogen to the fibrinogen receptor depends on an Arg-Gly-Asp-Ser (RGDS) tetrapeptide recognition motif. Structural modifications of the RGDS lead have led to the discovery of a non-peptide RGD mimetic GP IIb/IIIa antagonist 44 (S 1197). Compound

  血小板纤维蛋白原受体（GP IIb / IIIa受体）的拮抗剂有望成为一种有前途的新型抗血栓药。纤维蛋白原与纤维蛋白原受体的结合取决于Arg-Gly-Asp-Ser（RGDS）四肽识别基序。RGDS导联的结构修饰导致发现了非肽RGD模拟GP IIb / IIIa拮抗剂44（S 1197）。化合物44以剂量依赖和可逆的方式抑制人和狗的血小板聚集以及125I-纤维蛋白原与ADP激活的人凝胶过滤的血小板和分离的GP IIb / IIIa的结合，K（i）的K（i）值为9 nM和0.17 nM ， 分别。使用QXP进行药效团映射的程序以及应用GRID / GOLPE方法进行的3D-QSAR分析产生了稳定的，相当可预测的模型，并揭示了对绑定非常重要的结构特征。在乙内酰脲核和C-末端的疏水取代均增加了对血纤蛋白原受体的亲和力。结晶乙酯前药48（HMR 1794）是一种口服活性抗血栓药，是治疗人类血栓性疾病的有前途的候选药物。
• Amino acid derivatives which have renin inhibiting activity
  申请人：Hoffmann-La Roche, Inc.

  公开号：US05140011A1

  公开（公告）日：1992-08-18

  The compounds of the formula ##STR1## wherein A, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the significance given in claim 1, in the form of optically pure diastereomers, mixtures of diastereomers, diastereomeric racemates or mixtures of diastereomeric racemates as well as pharmaceutically usable salts thereof inhibit the activity of the natural enzyme renin and can accordingly be used in the form of pharmaceutical preparations in the control or prevention of high blood pressure and cardiac insufficiency.

  公式##STR1##的化合物，其中A、R.sup.1、R.sup.2、R.sup.3和R.sup.4的含义如权利要求1所述，以光学纯对映异构体、对映异构体混合物、对映异构体外消旋混合物或对映异构体外消旋混合物的形式，以及它们的药用盐，能够抑制天然酶肾素的活性，因此可以以药物制剂的形式用于控制或预防高血压和心脏衰竭。
• Compounds Which Selectively Modulate The CB2 Receptor
  申请人：BARTOLOZZI Alessandra

  公开号：US20100076029A1

  公开（公告）日：2010-03-25

  Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

  公式（I）的化合物已被披露。根据本发明的化合物与CB2受体结合，并且是CB2受体的激动剂、拮抗剂或反向激动剂，可用于治疗炎症。那些是激动剂的化合物还可用于治疗疼痛。